Beaumont Asset Management L.L.C. Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Beaumont Asset Management L.L.C. lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,465 shares of the biopharmaceutical company’s stock after selling 994 shares during the quarter. Beaumont Asset Management L.L.C.’s holdings in Pfizer were worth $733,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Parkside Financial Bank & Trust increased its position in shares of Pfizer by 21.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 51,050 shares of the biopharmaceutical company’s stock valued at $1,470,000 after purchasing an additional 9,073 shares during the last quarter. Stockman Wealth Management Inc. increased its position in shares of Pfizer by 5.8% during the 4th quarter. Stockman Wealth Management Inc. now owns 220,760 shares of the biopharmaceutical company’s stock valued at $6,356,000 after purchasing an additional 12,088 shares during the last quarter. Larson Financial Group LLC increased its position in shares of Pfizer by 11.4% during the 4th quarter. Larson Financial Group LLC now owns 22,668 shares of the biopharmaceutical company’s stock valued at $653,000 after purchasing an additional 2,325 shares during the last quarter. PDS Planning Inc increased its position in shares of Pfizer by 3.9% during the 4th quarter. PDS Planning Inc now owns 25,608 shares of the biopharmaceutical company’s stock valued at $737,000 after purchasing an additional 968 shares during the last quarter. Finally, Stephens Consulting LLC increased its position in shares of Pfizer by 26.0% during the 4th quarter. Stephens Consulting LLC now owns 4,845 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.06 during midday trading on Tuesday, reaching $26.32. 23,806,408 shares of the stock traded hands, compared to its average volume of 42,028,664. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a market capitalization of $149.04 billion, a PE ratio of 73.11, a P/E/G ratio of 1.17 and a beta of 0.61. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37. The company’s 50 day moving average is $27.08 and its 200 day moving average is $28.56.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.14 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.